LC
SYRE icon

Lindbrook Capital’s Spyre Therapeutics SYRE Stock Holding History

Lindbrook Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.26K Buy
+78
New +$1.62K ﹤0.01% 2403
2024
Q4 		– Sell
-19
Closed -$559 – 2904
2024
Q3 		$559 Buy
+19
New +$529 ﹤0.01% 2636

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lindbrook Capital's SYRE Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Spyre Therapeutics (SYRE) in Q1 2025: 78 shares worth $1.26K. The stake represents ﹤0.01% of the portfolio and ranks #2403 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in SYRE as recently as Q3 2024.

Lindbrook Capital first reported a position in SYRE in Q3 2024 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

  • Lindbrook Capital held 78 shares of Spyre Therapeutics worth $1.26K as of Q1 2025.
  • Spyre Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • Spyre Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2403 holding.
  • Lindbrook Capital first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.